Response to: Monoclonal antibodies targeting CD20

@inproceedings{Neumann2013ResponseTM,
  title={Response to: Monoclonal antibodies targeting CD20},
  author={Christiane Neumann and Alfred Lammens and Wolfgang Schaefer and Guy J Georges and Manfred Schwaiger and Ekkehard Moessner and Karl-Peter Hopfner and Pablo Uma{\~n}a and G. Niederfellner},
  booktitle={mAbs},
  year={2013}
}
the standard rituximab regimen of 375 mg/mm2 based solely on a historical comparison of complete response (CR)/uncon-firmed CR rates from non-randomized Phase 1/2 clinical trials in (relapsed/refractory) follicular non-Hodgkin lymphoma (NHL) patients as it is stated in the letter of Goldenberg and colleagues. In line with this, the cited publications by Morschhauser et al. 5 and Negrea et al. 6 do not claim superiority over rituximab. To claim superiority, the authors would have to provide… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-9 of 9 references

Results from a Phase I / II study ( BO 20999 ) of RO 5072759 ( GA 101 ) monotherapy in relapsed / refractory indolent non - Hodgkin ’ s lymphoma

G Salles, F Morschhauser, +3 authors H Tilly
Ann Oncol • 2011

Results from a phase II study ( BO 20999 ) of RO 5072759 ( GA 101 ) monotherapy in relapsed / refractory aggressive non - Hodgkin ’ s lymphoma

G Cartron, C Thieblemont, +3 authors R Bouabdallah
Ann Oncol • 2011

CD 20 - targeted therapy : the next generation of antibod

T vanMeerten, A Hagenbeek
Semin Hematol • 2010

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009

Similar Papers

Loading similar papers…